{
    "nctId": "NCT01698164",
    "briefTitle": "Multi-centre Clinical Trial on Hormone Replacement Treatment in China",
    "officialTitle": "Multi-centre Clinical Trial on Hormone Replacement Treatment in China",
    "overallStatus": "UNKNOWN",
    "conditions": "Menopausal Syndrome, Cardiovascular Disease, Osteoporosis, Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE4",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 1200,
    "primaryOutcomeMeasure": "Change from Baseline in risk factors of cardiovascular disease at 12 months and 24 months",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* going through amenorrhea above 6 months and within 5 years,\n* aged 40 to 60 years,\n* going though postmenopausal symptoms,\n* serum E2 concentration \\<30pg/ml,\n* serum FSH concentration \\>40IU/L.\n\nExclusion Criteria:\n\n* uterine fibroid diameter\u22655cm,\n* history of diabetes or hypertension,\n* history of thromboembolism, severe endometriosis, epilepsy, asthma, hyperprolactinemia,\n* first degree relative had a history of breast cancer,\n* being in severe or unstable condition of somatic diseases,\n* receiving HRT in the past 3 month,\n* drug or alcohol abuse in the past 3 month,\n* endometrial thickness \u22650.5cm after withdrawal bleeding,\n* being allergic to the medicine,\n* participating in other clinical trials within 1 month ago.",
    "sex": "FEMALE",
    "minimumAge": "40 Years",
    "stdAges": "ADULT"
}